Destone

Potassium Citrate

Method of action: Potassium Deficiency, Urologicals

Treatment option: Acidosis, Hypokalemia, Prevention Of Hypokalemia

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Destone

Quick Facts

Property	Description
Active Ingredient	Potassium Citrate (Tripotassium Citrate Monohydrate)
Form	Extended-release tablets, Oral Solution, Powder
Pharmacological Class	Urinary Alkalinizing Agent
Origin	Synthetic alkali salt

Destone: Classification and Core Identity

Destone is a specific prescription-only medication whose active component is Potassium Citrate, which is classified as a Urinary Alkalinizing Agent. The drug is chemically known as Tripotassium Citrate Monohydrate and functions as an electrolyte-modulating agent by supplying both potassium and the necessary citrate component. Its specialized role involves altering the body's internal acid-base dynamics, distinguishing it from general mineral supplements.

Composition and Physical Form

The foundation of Destone is its single active ingredient, Potassium Citrate, a synthetic alkali salt derived from Citric Acid. Destone is primarily available as an oral pharmaceutical preparation, most frequently manufactured as extended-release tablets for oral administration (per os). This specialized delivery system, designed with an excipient matrix, ensures the gradual and uniform release of the active ingredient within the digestive system over an extended period. For patients requiring alternatives, generic equivalents are also documented as oral solutions and powder for oral solution.

What is the General Purpose of Destone?

The general purpose of Destone is to create a chemically unfavorable environment for the crystallization of mineral structures in the urinary system. The medication achieves this through a high-level physiological action known as systemic alkalinization, where the metabolized citrate raises the pH (lowers the acidity) of the urine. This adjustment is essential because the solubility of key urinary components is highly dependent on pH. By increasing both the alkalinity and the concentration of citrate—a potent natural inhibitor—the drug assists in keeping specific minerals dissolved, thus supporting healthy urinary function.

Regulatory References

What side effects are possible with Destone?

Possible side effects and safety information

The safety profile for Destone (Potassium Citrate) is defined by its effects on the gastrointestinal system and its systemic impact on electrolyte balance, as documented in official regulatory sources.

Adverse Reaction Scope

The most frequently reported adverse reactions are generally mild to moderate gastrointestinal complaints, often classified as Common in clinical use. These typically involve the Gastrointestinal Disorders system-organ class and may include abdominal discomfort, nausea, vomiting, diarrhea, and flatulence.

Category	Serious Adverse Reactions (Label-Documented)
Metabolism & Nutrition	Hyperkalemia (elevated serum potassium), a serious, potentially fatal electrolyte imbalance.
Gastrointestinal	Severe localized Gastrointestinal Lesions (e.g., ulceration, obstruction, hemorrhage, or perforation), particularly associated with the extended-release tablet formulation.

Population-Specific Safety Considerations

The official label documents strict restrictions for certain patient populations:

Absolute Contraindications: The medication is contraindicated in individuals with severe renal impairment (due to high hyperkalemia risk), pre-existing active hyperkalemia, untreated urinary tract infection, or any condition causing delayed gastrointestinal transit (due to the risk of localized lesions).
Interactions: Concomitant use with other potassium-sparing agents or medications that increase serum potassium (such as certain blood pressure medicines) is restricted due to the heightened risk of severe systemic hyperkalemia.

This framework separates the common, manageable gastrointestinal effects from the clinically significant risks of systemic electrolyte imbalance and localized injury, establishing the boundaries for safe use.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information emphasizes that the primary risk associated with Destone (Potassium Citrate) overdosage is the rapid development of hyperkalemia (excess potassium in the blood), which is classified as a medical emergency. This condition may initially be asymptomatic but can quickly lead to severe or lethal outcomes.

Documented Overdose Manifestations

System	Manifestation
Cardiovascular	Tall peaked T waves, P wave loss, widened QRS complex (ECG changes), Cardiac arrest, Cardiovascular collapse.
Gastrointestinal	Severe vomiting, abdominal pain, gastrointestinal bleeding.
Systemic	Listlessness, muscle weakness, mental confusion, eventual muscle paralysis.

Mandatory Emergency Actions

Urgent medical attention is required immediately upon the detection of hyperkalemia or the onset of severe gastrointestinal signs, such as vomiting or bleeding. Regulators mandate that the drug must be discontinued at once. No specific antidote is known, and the management focuses on treatment protocols for hyperkalemia, which include close monitoring for arrhythmias, intravenous administration of calcium gluconate, and the use of insulin/dextrose solutions.

Potentially fatal hyperkalemia is a greater risk in individuals with predisposing conditions that impair potassium excretion, including chronic renal failure or adrenal insufficiency, as stated in the prescribing information.

Therapeutic Uses of Destone

Destone (Potassium Citrate) is applied in addressing conditions involving recurrent or episodic manifestations, playing a role in managing symptoms related to systemic imbalance. It is commonly used to help with the management of specific stone types and related metabolic conditions.

Managing Risk Factors for Recurrent Urinary Stones

This supportive therapy is primarily applied in addressing conditions characterized by recurrent or episodic stone formation, including hypocitraturic calcium oxalate nephrolithiasis, uric acid lithiasis, and renal tubular acidosis (RTA) with calcium stones. Destone is relevant when symptoms are marked by increased physiological stress associated with conditions involving systemic or localized discomfort. This approach supports general well-being during symptomatic phases by helping to manage the risk of recurrent episodes.

“This approach is relevant for easing the disruptive manifestations associated with high urinary acid levels and may assist with managing the stone burden.”

Patient Benefit and Clinical Context

Destone is commonly used in clinical settings that involve long-term supportive management for patients who are chronic stone formers. It is applied in addressing systemic discomfort by helping to manage symptoms that interfere with daily functioning, which contributes to easing the overall symptom load. This therapeutic approach is relevant for easing symptoms that interfere with daily functioning and may assist with reducing the formation of new stones.

Quick Fact: Support for Episodic Manifestations
Primary Use: Assists with the management of recurrent stone episodes in high-risk patients.
Patient Benefit: Supports patients during episodes of heightened discomfort by assisting with maintaining functional stability.

Regulatory References

official FDA prescribing information

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Destone (Potassium Citrate)

Eligibility for Destone is determined by official regulatory criteria, primarily related to the patient’s ability to manage potassium levels and the integrity of the gastrointestinal tract. Use is generally established for adults who meet the criteria for its approved uses.

Classification	Regulatory Statement	Population Type
Contraindicated	Hyperkalemia, chronic renal failure, uncontrolled diabetes mellitus, or use with potassium-sparing diuretics.	Metabolic/Comorbidity
Contraindicated	Renal Insufficiency (GFR less than 0.7 mL/kg/min).	Organ Function
Contraindicated	Peptic ulcer disease; conditions causing delayed or arrested passage through the GI tract.	Gastrointestinal
Use Not Established	Safety and effectiveness have not been established in the pediatric population.	Age-Related
Restricted Use	The medicine should be avoided in patients with severe myocardial damage or heart failure.	Comorbidity
Conditional Use	For pregnant and nursing mothers, use is authorized only if clearly needed due to unknown effects on the fetus or human milk.	Life Stage

Eligibility is defined by regulatory agencies to avoid potentially fatal hyperkalemia and serious GI complications. The contraindications are absolute and must be adhered to, while restrictions define populations that require special consideration or exclusion based on official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Destone (Potassium Citrate) primarily identifies interactions that contribute to an increased risk of hyperkalemia (elevated potassium levels in the blood) due to additive pharmacodynamic effects or impaired potassium excretion.

Formally Documented Interaction Restrictions

Classification	Interacting Agents or Conditions	Regulatory Restriction
Contraindicated Combinations	Potassium-sparing diuretics (e.g., Spironolactone, Amiloride)	Co-administration is prohibited due to the severe, potentially fatal risk of hyperkalemia.
Population Constraint	Severe Renal Insufficiency (GFR < 0.7 ml/kg/min)	Use is contraindicated, as impaired kidney function prevents safe excretion of the potassium load.
Additive Hyperkalemia Risk	RAAS Inhibitors (e.g., ACE Inhibitors, ARBs), NSAIDs (e.g., Ibuprofen)	Concurrent use requires close monitoring of serum potassium levels due to increased risk of potassium retention.

Timing and Administration Risk

Co-administration with agents that significantly slow gastrointestinal transit time, such as anticholinergic medications, is expected to increase the risk of localized gastrointestinal irritation and lesions. Additionally, co-administration with any other potassium supplements or potassium-containing products significantly heightens the systemic risk of hyperkalemia. The official interaction profile is dominated by constraints related to managing the overall potassium burden.

Mechanism of Action

The mechanism of Destone (Potassium Citrate) is a physiochemical and metabolic process that operates by altering the chemical composition of the urine, independent of classical receptor binding.

Metabolic Conversion and Systemic Alkalinization

The core mechanism begins with the metabolic oxidation of the absorbed citrate component, which generates an alkaline load equivalent to bicarbonate ions ( HCO3^-). This systemic shift in acid-base balance is the initial metabolic step, leading to increased alkalinity that raises the pH (lowers acidity) of the urine.

Renal Pathway Modulation and Enhanced Citraturia

This mechanism directly enhances the concentration of the active inhibitor in the urine. The systemic alkalinization indirectly modulates the activity of the NaDC-1 transporter in the proximal renal tubule, thereby suppressing the reabsorption of filtered citrate back into the blood. This effect ensures a higher concentration of citrate is excreted.

Physiochemical Inhibition of Mineral Aggregation

The final physiological effect is achieved when the increased urinary citrate acts as a chelation agent. It binds to free calcium ions ( Ca^2+), reducing their concentration, while also directly interfering with the spontaneous nucleation and growth of crystalline structures. The combined action of pH elevation and calcium chelation lowers the urine's supersaturation index.

Dosage and Administration Information

How to Use Destone (Potassium Citrate): Administration Guidelines

Destone (Potassium Citrate) is strictly administered via the oral route and is available primarily as extended-release tablets and, alternatively, as an oral solution or powder. The primary purpose of these instructions is to ensure correct administration and therapeutic targeting without addressing efficacy or safety.

Dosing and Scheduling

Dosage is determined by the severity of a patient's condition, specifically the baseline 24-hour urinary citrate level.

Condition	Starting Adult Dose (Total Daily)	Frequency
Mild to Moderate	30 mEq	Two or Three Times Daily
Severe	60 mEq	Two or Three Times Daily

Daily doses exceeding 100 mEq have not been studied and are not recommended. The dose is adjusted by a physician to maintain urinary pH between 6.0 and 7.0 and citrate levels between 320 mg/day and 640 mg/day.

Required Administration Conditions

Timing: The medicine must be taken with a meal or within 30 minutes after eating to minimize gastrointestinal upset.
Tablet Handling: Extended-release tablets must be swallowed whole. They must not be crushed, chewed, or sucked, as this destroys the controlled-release mechanism. The inert wax matrix may be observed intact in the stool.
Preparation: Oral solutions or powders must be adequately diluted with water or juice before use.
Adjunctive Measures: The treatment regimen includes instructions to maintain a high fluid intake (resulting in a urine volume of 2 liters/day or more) and limit dietary salt/sodium intake.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Destone

Evidence for use in Hypocitraturic Calcium Oxalate Nephrolithiasis

Studies of Destone were evaluated in adults who have conditions characterized by fluctuating or episodic manifestations, focusing on recurrent calcium stones associated with low levels of urinary citrate. Researchers applied Randomized Controlled Trials (RCTs) and systematic reviews in research exploring patterns in new stone formation and outcomes related to systemic or functional imbalance. Studies examined measured shifts in urinary pH and citrate levels in the observed populations. Some trials described stone formation patterns over extended follow-up periods, with key research spanning up to three or four years. The research provides context but not individual predictions for stone activity over time.

Evidence for use in Uric Acid Lithiasis

Destone was observed in studies of adults with acute or disruptive episodes related to uric acid stones. These studies monitored outcomes related to physical discomfort and systemic imbalance, focusing on the size of existing stones and patterns in new stone formation. Findings describe patterns observed in the studies related to changes in stone size and measured increases in urinary pH, which helps contextualize how stone status was monitored in the study settings. Evidence quality varies across studies for this indication, and there is limited information for specific subgroups.

Evidence in Other Relevant Clinical Contexts

Destone was evaluated in research exploring its role in Renal Tubular Acidosis (RTA), where studies examined outcomes related to systemic imbalance and stone formation. Research focused on target urinary pH and citrate levels and tracking the prevention of new stone formation. Destone was also observed in research involving patients following stone removal procedures, such as Extracorporeal Shock Wave Lithotripsy (ESWL). Studies monitored patterns in new stone formation over intermediate time intervals (typically 12 months) in these post-procedure groups.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Destone (FAQ)

Q: Can I take Destone for migraines?

Official documents state that Destone is indicated for the acute treatment of migraine headaches. This means the use is targeted toward treating a migraine that is occurring. Official information clarifies that Destone is not indicated for the prevention of future migraine attacks.

Q: Can children 2 years old use Destone?

The official product information addresses the use of Destone in pediatric patients. The regulatory labeling indicates that the safety and effectiveness of the drug have not been established in pediatric patients below the specific minimum age that is listed. Official labeling provides the specific minimum age for which the drug has been studied and approved for use.

How should Destone be stored and disposed of?

How to Store and Dispose of Destone?

Storing Destone properly is necessary to maintain its labeled quality and stability, according to official regulatory requirements.

Storage and Stability Requirements
Temperature: Store at controlled room temperature, between 20 C and 25 C (68 F and 77 F). Excursions are permitted between 15 C and 30 C.
Protection: Keep Destone in its original container or blister packaging to protect it from moisture and light. Do not freeze the medication.
Handling: Keep Destone and all medications out of the sight and reach of children.

For disposal, unused or expired Destone must be discarded safely according to government guidelines. Patients should utilize a drug take-back program when available. If a take-back program is not available, the medication must be mixed with an unappealing substance, placed in a sealed bag, and then discarded in the household trash, following the documented instructions to prevent unauthorized access.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Taiwan

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z